CEBPA Antikörper
Kurzübersicht für CEBPA Antikörper (ABIN2664083)
Target
Alle CEBPA Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Kreuzreaktivität
- Maus
-
Kreuzreaktivität (Details)
- weakly cross-reacts with mouse
-
Aufreinigung
- The antibody was purified by affinity chromatography.
-
Isotyp
- IgG2a kappa
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 0.5 mg/mL
-
Buffer
- Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- The antibody solution should be stored undiluted between 2°C and 8°C.
-
-
- CEBPA (CCAAT/enhancer Binding Protein (C/EBP), alpha (CEBPA))
-
Andere Bezeichnung
- C/EBPalpha
-
Hintergrund
- The CCAAT-enhancer binding proteins (C/EBP) are members of the basic region/leucine zipper (bZIP) transcription factors, that bind to the consensus CCAAT sequence in DNA. C/EBPα is expressed in two isoforms: p42 and p30 by ultilizing different translational start codons. The C/EBPα p30 isoform has little to no transactivating activity and acts as an inhibitor. C/EBPα regulates expression of various myeloid-specific genes and is required for myeloid differentiation. C/EBPα has been found to play a key role in adipogenesis, since inhibition of C/EBPα blocks adipocyte differentiation. C/EBPα also regulates cell cycle progression through interactions with cyclin-dependent kinases (CDK) and by inducing the expression of CDK inhibitor p21. Mutations in the C/EBPα gene are associated with the development of acute myeloid leukemia.
-
Pathways
- Brown Fat Cell Differentiation, Positive Regulation of fat Cell Differentiation
Target
-